DBV Technologies (NASDAQ:DBVT) Earns Market Outperform Rating from JMP Securities

DBV Technologies (NASDAQ:DBVT)‘s stock had its “market outperform” rating reissued by JMP Securities in a research report issued on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock. JMP Securities’ price objective would indicate a potential upside of 194.12% from the stock’s current price.

Other analysts also recently issued reports about the company. StockNews.com assumed coverage on DBV Technologies in a report on Sunday. They set a “hold” rating for the company. HC Wainwright lifted their target price on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT traded down $0.09 during midday trading on Tuesday, reaching $3.40. The stock had a trading volume of 14,644 shares, compared to its average volume of 45,642. The company’s 50 day moving average price is $3.46 and its 200 day moving average price is $4.06. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $10.70. The firm has a market cap of $69.94 million, a price-to-earnings ratio of -0.78 and a beta of 0.64.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.